98%
921
2 minutes
20
Background And Aims: The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress. Hypertrophic cardiomyopathy (HCM) is a common heart condition, affecting approximately 15% of the general cat population. Feline HCM shares phenotypical and genotypical similarities with human HCM, but the disease mechanisms for both species are incompletely understood. Our goal was to characterize global changes in metabolome between healthy control cats and cats with different stages of HCM.
Methods: Serum samples from 83 cats, the majority (70/83) of which were domestic shorthair and included 23 healthy control cats, 31 and 12 preclinical cats with American College of Veterinary Internal Medicine (ACVIM) stages B1 and B2, respectively, and 17 cats with history of clinical heart failure or arterial thromboembolism (ACVIM stage C), were collected for untargeted metabolomic analysis. Multiple linear regression adjusted for age, sex and body weight was applied to compare between control and across HCM groups.
Results: Our study identified 1253 metabolites, of which 983 metabolites had known identities. Statistical analysis identified 167 metabolites that were significantly different among groups (adjusted P < 0.1). About half of the differentially identified metabolites were lipids, including glycerophospholipids, sphingolipids and cholesterol. Serum concentrations of free fatty acids, 3-hydroxy fatty acids and acylcarnitines were increased in HCM groups compared with control group. The levels of creatine phosphate and multiple Krebs cycle intermediates, including succinate, aconitate and α-ketoglutarate, also accumulated in the circulation of HCM cats. In addition, serum levels of nicotinamide and tryptophan, precursors for de novo NAD+ biosynthesis, were reduced in HCM groups versus control group. Glutathione metabolism was altered. Serum levels of cystine, the oxidized form of cysteine and cysteine-glutathione disulfide, were elevated in the HCM groups, indicative of heightened oxidative stress. Further, the level of ophthalmate, an endogenous glutathione analog and competitive inhibitor, was increased by more than twofold in HCM groups versus control group. Finally, several uremic toxins, including guanidino compounds and protein bound putrescine, accumulated in the circulation of HCM cats.
Conclusions: Our study provided evidence of deranged energy metabolism, altered glutathione homeostasis and impaired renal uremic toxin excretion. Altered lipid metabolism suggested perturbed structure and function of cardiac sarcolemma membrane and lipid signalling.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911622 | PMC |
http://dx.doi.org/10.1002/ehf2.15135 | DOI Listing |
J Cardiovasc Pharmacol
September 2025
Graduate School of Cardiology, Bengbu Medical University, Bengbu 233000, Anhui, China.
Chronic stress-induced cardiac hypertrophy remains a critical precursor to heart failure, with current therapies limited by incomplete mechanistic targeting. Cyclin-dependent kinases (CDKs), pivotal regulators of cell cycle and stress signaling, are emerging therapeutic targets in cardiovascular pathologies. Using bioinformatics analysis of human hypertrophic cardiomyopathy datasets (GSE5500, GSE136308) and a murine transverse aortic constriction (TAC) model, we investigated the therapeutic effects of the CDK inhibitor R547 (10 mg/kg, intraperitoneal every 3 days) on pressure overload-induced cardiac remodeling.
View Article and Find Full Text PDFJTCVS Open
August 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
Background: Proper risk stratification tools for patients with obstructive hypertrophic cardiomyopathy (oHCM) undergoing septal myectomy are lacking. Our objective was to assess the predictive value of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) on perioperative outcomes and late survival in patients with oHCM undergoing transaortic septal myectomy.
Methods: Between 2008 and 2021, 834 patients with preoperative NT-proBNP measurements underwent septal myectomy.
Heart Rhythm
September 2025
Tufts Medicine CardioVascular Center, Division of Cardiology, Boston, MA.
Int J Cardiol
September 2025
Department of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republic.
Background: Alcohol septal ablation (ASA) is an established therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) in patients unresponsive to medical treatment. However, comprehensive assessment of ASA outcomes remains challenging. This study aimed to evaluate the impact of institutional experience and patient characteristics on achieving complete clinical and haemodynamic response (CCHR), a novel composite outcome integrating long-term symptomatic, haemodynamic, safety, and major clinical endpoints, including survival and resuscitation.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Division of Non-Invasive Cardiology, Cardiology Centre, Department of Medicine, University of Szeged, Hungary. Electronic address:
Background: Real-world data on the efficacy of mavacamten, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), are relatively scarce, particularly in patients with extreme left ventricular outflow tract (LVOT) gradients and concerning its short-term effects.
Patients/methods: We investigated a cohort of twenty-five oHCM patients [15 men (60 %), mean age: 55 ± 11 years], with a resting or provoked LVOT gradient of >100 mmHg, receiving mavacamten treatment. Patients underwent a complete standard and 2D-speckle tracking echocardiographic examination after one week (W1) of treatment initiation and at subsequent four-week intervals.